Kyrgyzstan Medical Device Inspections: The Cabinet Resolution No. 450 Procedure

1. Key takeaways

On June 29, 2026, the Cabinet of Ministers of the Kyrgyz Republic adopted Resolution No. 450, On the Approval of the Inspection Procedures in the Field of Medical Device Circulation, issued under Part 3 of Article 18 of Law No. 216, repealing paragraph 1 of Government Order No. 120 of March 15, 2019, entering into force 10 days after official publication. The significance is that inspection is now a standalone procedure, separate from registration, covering production and circulation and initiated at any point in the distribution life cycle.

2. Legal basis

1. Law of the Kyrgyz Republic On the Circulation of Medical Devices, No. 216 of December 29, 2023, Part 3 of Article 18 — the statutory source of the Cabinet’s authority to establish inspection procedures.
2. Cabinet Resolution No. 450 of June 29, 2026, On the Approval of the Inspection Procedures in the Field of Medical Device Circulation:
   • paragraph 1: approves the Inspection Procedures in the Field of Medical Device Circulation;
   • paragraph 2: instructs the Ministry of Health to take the accompanying measures within two months;
   • paragraph 3: implementation of the resolution is carried out within the annual budget allocations determined by the Ministry of Health;
   • paragraph 4: repeals paragraph 1 of Government Order No. 120 of March 15, 2019;
   • paragraph 5: the resolution enters into force 10 days after its official publication.
3. Cabinet Resolution No. 513 of August 27, 2024, Annex 1 — the production inspection stage within the registration procedure.
4. The draft revision published for public comment by the Ministry of Health in 2026 (draft status, not yet in force) is intended to recognize positive production inspection reports issued by the competent authorities of other Union member states, subject to confirmation by at least two member states; production inspection applies to devices of potential risk classes 2a (sterile), 2b and 3, with an inspection period of not more than 90 calendar days not counted toward the overall registration timeline; if adopted, the draft will require corresponding amendments to Cabinet Resolution No. 450.

3. Expert insights

Insight 1: the legislative path of Resolution No. 450 shows that inspection power is an independent administrative power.

The resolution rests on Part 3 of Article 18 of Law No. 216, not on the registration provisions. That is a clear signal: the basis of inspection power is the mandate to supervise circulation, not the mandate to run the registration procedure. The positioning of a company facing an inspection changes accordingly — what it faces is not an extension of the registration review but an independent administrative inspection with its own procedures, participants and handling of outcomes.

Insight 2: the new procedure and the inspection stage inside the registration procedure are one set of rules applied in two scenarios.

The production inspection inside the registration procedure (Annex 1 to Cabinet Resolution No. 513) answers whether a production site can support the registration; inspections under Resolution No. 450 answer whether devices and actors in circulation meet the requirements. The two can reference each other’s conclusions, but their triggers and outcome handling differ. For the registration scenario, the emphasis is on production conditions and the quality management system; for the circulation scenario, on product conformity, labeling, traceability and the performance of vigilance obligations.

Insight 3: because the inspection period is not counted toward the registration timeline, project scheduling must show it as a separate item.

The explanatory materials for the 2026 draft revision state expressly that the inspection period is not counted toward the overall registration timeline and is not more than 90 calendar days (draft status). Combined with the standard procedure of up to 50 calendar days from confirmation of fee payment, a class 2b or class 3 project requiring an on-site inspection has a theoretical ceiling near 140 calendar days, excluding the deficiency response period and the payment period. Treating the inspection period as extra time outside the registration timeline is the precondition for getting the schedule right.

Insight 4: the proposed two-state confirmation mechanism is a substantive step toward mutual recognition of conclusions within the Union.

The draft proposes that for devices without one of the eight-country approvals requiring production inspection, a positive production inspection report issued by the competent authority of another Union member state may be submitted, subject to confirmation by at least two member states, to avoid duplicate inspections. If the mechanism takes effect, companies already inspected under the Union framework in Russia or Kazakhstan gain a real time advantage. This supports doing Union member state projects first, then entering Kyrgyzstan.

Insight 5: the two-month instruction to the Ministry of Health signals that more documents are coming.

Paragraph 2 of the resolution requires the Ministry of Health to take measures within two months, which means that operational rules for inspection, the methodology for inspection plans, the assignment of inspectors, and inspection report formats will appear in sequence. After the new rules take effect, companies should proactively track the accompanying publications of the competent authority rather than relying on experience from the era of Order No. 120.

4. Practical recommendations

First, upgrade inspection readiness from a project action to a standing capability. An inspection can be triggered at the registration stage or initiated independently during circulation. Assemble production site documentation, quality management system certificates, batch records, traceability records, and complaint and vigilance files into an inspection package that can be produced at any time, maintained by the authorized representative.

Second, for projects requiring on-site inspection, build the schedule on the worst case. For class 2a (sterile), 2b and 3 devices, plan on the basis of the standard procedure of 50 calendar days plus 90 calendar days for inspection plus a buffer for deficiency responses and payment, and communicate this expectation internally.

Third, companies already inspected under the Union framework should prepare mutual recognition evidence in advance. Compile existing production inspection reports (issuing authority, date, scope, conclusions) and assess whether they can meet the requirement of confirmation by at least two member states, so as to be ready when the mechanism enters into force.

Fourth, track the Ministry of Health accompanying documents, especially the division of inspection plans and the scope of inspectable entities. Inspection resources are limited, and the competent authority will normally allocate inspection frequency and targets by risk, so knowing one’s own category helps predict inspection likelihood and focus preparation.

5. Verification checklist

• □ Obtain the original text of Cabinet Resolution No. 450 (June 29, 2026) and its annexed Inspection Procedures in the Field of Medical Device Circulation;
• □ Confirm the entry into force mechanism of the resolution: 10 days after its official publication;
• □ Confirm the repealed instrument: paragraph 1 of Government Order No. 120 of March 15, 2019, and do not carry over its precedents;
• □ Build two material packages by inspection scenario: registration scenario (production conditions and quality system) and circulation scenario (conformity, labeling, traceability, vigilance);
• □ For projects requiring on-site inspection: schedule on the basis of 50 calendar days plus 90 calendar days plus a buffer for deficiency responses and payment;
• □ Track the accompanying documents issued by the Ministry of Health within the two-month period set in paragraph 2 of Resolution No. 450;
• □ Existing production inspection reports under the Union framework have been compiled, and the feasibility of mutual recognition with confirmation by at least two member states has been assessed.

Regulatory information verified as of October 29, 2026.

Our services cover pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, production site inspection coordination, quality management system conformity support, post-market surveillance and device vigilance system setup, import and distribution compliance, official fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registrations. We maintain a stable local cooperation network in Bishkek, Almaty, Tashkent and Moscow, work in Chinese, Russian and English, and provide executable solutions for the issues foreign manufacturers most often encounter in CIS markets, including authorized representative arrangements, the notarization and legalization chain for powers of attorney, localization of technical documentation, and inspection readiness.

We adhere to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Figures and timelines that cannot be verified are always marked as practical estimates, and experience-based values are never presented as legal requirements.

GRZAN provides registration support in Kyrgyzstan for medical device manufacturers, importers and authorized representatives. For project consultation on Kyrgyzstan or Eurasian Economic Union market access, contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services